Jason N. Mock

Partner

Zurück

Jason N. Mock

Partner

[email protected]

Washington, D.C. 202.295.4775

Praxisbereiche

Bildung

Rechtswissenschaftliche Fakultät der George Washington University (J.D., mit Auszeichnung)
- Member, Federal Circuit Bar Journal
- George S. Hastings IP Scholar
- Finnegan Prize for Intellectual Property Law
University of Georgia (Ph.D., summa cum laude)
- Pharmaceutical and biomedical science
University of Georgia (B.S., magna cum laude)
- Biotechnology, and agricultural and applied economics

Zulassungen

District of Columbia
Virginia
U.S. Patent- und Markenamt

Dr. Jason Mock ist Anwalt für geistiges Eigentum und unterstützt Unternehmen jeder Größe in allen Bereichen des Patentlebenszyklus. Ganz gleich, ob ein Kunde neue Patentrechte entwickelt und erwirbt, ein komplexes Portfolio verwaltet, eine Due-Diligence-Prüfung für eine Transaktion durchführt oder seine Rechte durchsetzt oder verteidigt – Jason verfügt über die Erfahrung, um seine Kunden zu beraten und ihnen als vertrauenswürdiger Berater zur Seite zu stehen.

Jason’s practice spans industries including pharmaceuticals, diagnostics, biotechnology, synthetic biology and biomanufacturing, food science, and agriculture. He has a depth of knowledge to help his clients keep pace in changing environments and realize value from their IP. Jason’s clients range from startups and universities to multinational corporations. He is a member of the firm’s Chemical, Biotechnology, & Pharmaceutical Practice and the PTAB Trials Practice.

Präsentationen und Veröffentlichungen

J. Mock, T. Yan, and K. Sharon, “IPR proactive defense measures – strategies and considerations for patent owners,” PTAB Trial Insights (May 2016)
J. Mock, “Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions,” PTAB Trial Insights (January 2016)
Author, “Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals,” The Federal Circuit Bar Journal (September 2015)
Co-author, “The Road Ahead for Kyle Bass’s IPRs,” Law360 (August 2015)
Co-author, “Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?” The National Law Review (August 2015)
Co-author, “Survey of State Laws Against Bad-Faith Patent Assertion,” Bloomberg BNA Patent, Trademark & Copyright Journal (August 2014)
Co-author, “Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells,” Mol. Pharmaceuticals (2014)
Co-author, “Evidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,” Integr. Biol. (2012)
Co-author, “Haloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,” Bioorg. and Med. Chem. Letters (2012)
Co-author, “Secretory Phospholipase A2 Responsive Liposomes,” J. Pharm. Sci. (2011)
Co-author, Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,” Cancer Bio. and Therapy (2011)